Whether thyroid-stimulating hormone (TSH) suppression therapy may change bone mineral density and cause osteoporosis signs in some patients with differentiated thyroid carcinoma (DTC) remains controversial. Here, the authors present the current research progress of DTC TSH suppression therapy associated changes in bone metabolism from the viewpoints of both experimental and clinical studies.